Skip to content

MEDILEV

Active Private limited companyfounded 2007active for 19 yearsTer Kamerenlaan 3, 1050 IxellesKBO/BCE: BE 0891.961.817

Lifetime

18 annual accounts with figures on one time axis
peak of €137,034 in 2011
€57,292▼ 22.5%
lowest -€176,434 in 2014
€40,008▼ 20.9%
peak of €287,053 in 2023
€189,961▼ 33.3%
€177,593▲ 116%
Board1 name since 2020
1 director
Documentsfilings and deeds
30-06-202631 days before the deadline
2025micro format
Gross margin from €73,925 to €57,292Dividend €134,681Equity from €284,633 to €189,961Debts from €82,318 to €177,593Investments €32,521Cash from €33,298 to €16,633

Key points

from the 2025 annual accounts

Equity

€189,961 ▼ 33.3%
284,6332024+40,008Profit-134,681Dividend189,9612025

MEDILEV paid out €134,681 in dividends. That is 337% of the 2025 profit.

Debts

€177,593 ▲ 116%
Other debts
+76,726
Suppliers
+2,192
The rest
+16,357

Debts rose by €95,275 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Investments

€32,521 4.5 times depreciation
2021202220242025

Green is investment, beige is depreciation. Machinery stands 713.4% higher than in 2024.

Liquidity

1.86 was 4.31 in 2024

Short-term debts rose from €82,318 to €177,593.

Filings

18 annual accounts since 2008
AprilJune31 JulyOctober2010201520202025

Three of the last ten came late. The 2022 accounts came in latest, 25 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,728 companies had the same profile as MEDILEV has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,728 companies, not a prediction for MEDILEV. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Board & ownership

Recent changes

Capital increase of €74,400 400 new shares · appointed as director · Founding capital of €18,600, 100 shares · General meeting of 04-12-2020 · Gazette deed
is in office as manager General meeting of 28-06-2019 · Gazette deed
Amendment of the articles is in office as manager · General meeting of 31-07-2018 · Gazette deed
Amendment of the articles is in office as manager · General meeting of 19-06-2017 · Gazette deed
All 34 events

Official details

Source: KBO
Status
Active since 10-09-2007Normal situation
Registered office
19 active companies are registered at this addressOf these, 2 started in the 12 months before 21 November 2026. Source: KBO register, as of 21 November 2026.
Activity
“L'exercice de la médecine par les associés qui la composent, dans le respect de…” (deed in French)From the articles, 8 activitiesNo NACE code in the KBO
Financial year end
31 December
Peppol
Not found in the Peppol Directory
Company details

Annual accounts 2025

≈ €170,000estimated
€367,554▲ 0.2%
Filing
Filed on 30-06-2026, 31 days before the end of the filing period
Financials

Insights on MEDILEV

MEDILEV files the micro format. That format states no turnover. The gross margin fell from €100,772 in 2008 to €57,292 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MEDILEV

What is the company number of MEDILEV?
The company number of MEDILEV is 0891.961.817. The VAT number is the same number with BE in front: BE 0891.961.817.
Where is MEDILEV based?
The registered office is at Ter Kamerenlaan 3, 1050 Ixelles.Company details
What is the legal form of MEDILEV?
MEDILEV is a private limited company (BV).
When was MEDILEV founded?
MEDILEV was founded on 10-09-2007.
Is MEDILEV still active?
Yes, MEDILEV is an active enterprise in the KBO register.
What is the turnover of MEDILEV?
The turnover in financial year 2025 is about €170,000. This figure is estimated from the gross margin of €57,292 and 2,989 comparable companies of the same size. It probably lies between €110,000 and €300,000. It is a rough estimate. In financial year 2019 turnover was €153,285.Financials
Is MEDILEV profitable?
In financial year 2025, MEDILEV made a profit of €40,008.
Where can I find the annual accounts of MEDILEV?
MEDILEV filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MEDILEV due?
MEDILEV must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.